Medipharm Labs Corp Asset Resilience Ratio
Medipharm Labs Corp asset resilience ratio. Medipharm Labs Corp (LABS) has an Asset Resilience Ratio of 23.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medipharm Labs Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medipharm Labs Corp (2018–2025)
Asset resilience ratio of Medipharm Labs Corp from 2018 to 2025. This chart shows how Medipharm Labs Corp's Asset Resilience Ratio has changed over time. Read how much debt does Medipharm Labs Corp carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medipharm Labs Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LABS total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$10.81 Million | 23.63% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$10.81 Million | 23.63% |
Asset Resilience Insights
- Good Liquidity Position: Medipharm Labs Corp maintains a healthy 23.63% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Medipharm Labs Corp Industry Peers by Asset Resilience Ratio
Compare Medipharm Labs Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Medipharm Labs Corp Asset Resilience Ratio by Year (2018–2025)
Medipharm Labs Corp asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Medipharm Labs Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 23.63% | CA$10.81 Million ≈ $7.82 Million |
CA$45.74 Million ≈ $33.09 Million |
+1.87pp |
| 2024-12-31 | 21.76% | CA$11.69 Million ≈ $8.46 Million |
CA$53.73 Million ≈ $38.87 Million |
-6.78pp |
| 2023-12-31 | 28.54% | CA$18.25 Million ≈ $13.20 Million |
CA$63.94 Million ≈ $46.25 Million |
-9.48pp |
| 2022-12-31 | 38.02% | CA$24.90 Million ≈ $18.01 Million |
CA$65.50 Million ≈ $47.38 Million |
-0.15pp |
| 2021-12-31 | 38.17% | CA$35.25 Million ≈ $25.50 Million |
CA$92.36 Million ≈ $66.81 Million |
+19.59pp |
| 2020-12-31 | 18.58% | CA$21.97 Million ≈ $15.89 Million |
CA$118.23 Million ≈ $85.53 Million |
-4.70pp |
| 2019-12-31 | 23.28% | CA$39.31 Million ≈ $28.43 Million |
CA$168.83 Million ≈ $122.13 Million |
+4.44pp |
| 2018-12-31 | 18.84% | CA$8.05 Million ≈ $5.82 Million |
CA$42.73 Million ≈ $30.91 Million |
-- |
About Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It a… Read more